| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2020 | AZEVAN PHARMACEUTICALS INC. | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | R44NS090616 | Advancing SRX246 to Commericialization | 000 | 5 | NIH | 4/8/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1 ) |
| | 2022 | 2019 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | R43NS110343 | A New Drug for the Treatment of Traumatic Brain Injury | 000 | 1 | NIH | 3/16/2022 | $0 |
| | 2022 | 2018 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 000 | 4 | NIH | 9/26/2022 | $1 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | R43NS110343 | A New Drug for the Treatment of Traumatic Brain Injury | 000 | 1 | NIH | 10/19/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $3,190,880 ) |
| | 2020 | 2020 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | R44NS090616 | Advancing SRX246 to Commericialization | 000 | 5 | NIH | 9/16/2020 | $3,190,881 |
| | 2020 | 2018 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 000 | 4 | NIH | 4/1/2020 | -$1 |
|
| Issue Date FY: 2019 ( Subtotal = $501,472 ) |
| | 2019 | 2019 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4731 | NORTHAMPTON | USA | R43NS110343 | A New Drug for the Treatment of Traumatic Brain Injury | 000 | 1 | NIH | 5/1/2019 | $501,472 |
|
| Issue Date FY: 2018 ( Subtotal = $764,163 ) |
| | 2018 | 2018 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4734 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 000 | 4 | NIH | 2/1/2018 | $764,163 |
| | 2018 | 2018 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4734 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 001 | 4 | NIH | 8/27/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,541,404 ) |
| | 2017 | 2017 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4734 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 001 | 3 | NIH | 2/27/2017 | $61,234 |
| | 2017 | 2017 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4734 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 002 | 3 | NIH | 6/22/2017 | $148,018 |
| | 2017 | 2017 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4734 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 000 | 3 | NIH | 2/8/2017 | $1,332,155 |
| | 2017 | 2013 | AZEVAN PHARMACEUTICALS INC | 116 RESEARCH DR | BETHLEHEM | PA | 18015-4734 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 000 | 4 | NIH | 11/10/2016 | -$3 |
|
| Issue Date FY: 2016 ( Subtotal = $2,214,354 ) |
| | 2016 | 2016 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 000 | 2 | NIH | 3/21/2016 | $2,214,354 |
|
| Issue Date FY: 2015 ( Subtotal = $1,115,185 ) |
| | 2015 | 2015 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | U44NS090616 | Tolerability of SRX246 in Huntington's Disease Patients | 000 | 1 | NIH | 8/10/2015 | $1,115,185 |
| | 2015 | 2013 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 000 | 4 | NIH | 6/24/2015 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $598,813 ) |
| | 2013 | 2013 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 000 | 4 | NIH | 7/3/2013 | $598,813 |
|
| Issue Date FY: 2012 ( Subtotal = $595,262 ) |
| | 2012 | 2012 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 000 | 3 | NIH | 7/16/2012 | $595,262 |
|
| Issue Date FY: 2011 ( Subtotal = $856,071 ) |
| | 2011 | 2011 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 001 | 2 | NIH | 7/13/2011 | $600,000 |
| | 2011 | 2011 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R41MH093049 | SCREENING NEW THERAPEUTICS FOR THE TREATMENT OF POST TRAUMATIC STRESS DISORDER | 000 | 1 | NIH | 5/24/2011 | $141,071 |
| | 2011 | 2011 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 002 | 2 | NIH | 9/20/2011 | $115,000 |
| | 2011 | 2010 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 000 | 1 | NIH | 7/11/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $349,195 ) |
| | 2010 | 2010 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH087001 | New Drugs for Stress-related Affective Illness | 000 | 1 | NIH | 5/1/2010 | $349,195 |
| | 2010 | 2009 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 8 | NIH | 9/3/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $1,021,700 ) |
| | 2009 | 2009 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 001 | 8 | NIH | 8/11/2009 | $795,315 |
| | 2009 | 2009 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 002 | 8 | NIH | 9/29/2009 | $226,385 |
| | 2009 | 2008 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 7 | NIH | 6/22/2009 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $797,078 ) |
| | 2008 | 2008 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 7 | NIH | 8/30/2008 | $797,078 |
|
| Issue Date FY: 2007 ( Subtotal = $801,007 ) |
| | 2007 | 2007 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 6 | NIH | 8/29/2007 | $801,007 |
|
| Issue Date FY: 2006 ( Subtotal = $449,093 ) |
| | 2006 | 2006 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 5 | NIH | 8/21/2006 | $449,093 |
|
| Issue Date FY: 2005 ( Subtotal = $449,073 ) |
| | 2005 | 2005 | AZEVVAN PHARMACEUTICALS INC | 111 RESEARCH DRIVE | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 3 | NIH | 9/21/2005 | $449,073 |
|
|
